Literature DB >> 23060033

Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera.

Carsten H Meyer1, Adrian Klein, Florian Alten, Zengping Liu, Boris V Stanzel, Hans M Helb, Christian K Brinkmann.   

Abstract

PURPOSE: Ozurdex, a novel dexamethasone (DEX) implant, is released by a drug delivery system into the vitreous cavity. We analyzed the mechanical release aperture of the novel applicator, obtained real-time recordings using a high-speed camera system and performed kinematic analysis of the DEX application.
DESIGN: Experimental study.
METHODS: : The application of intravitreal DEX implants (6 mm length, 0.46 mm diameter; 700 μg DEX mass, 0.0012 g total implant mass) was recorded by a high-speed camera (500 frames per second) in water (Group A: n = 7) or vitreous (Group B: n = 7) filled tanks. Kinematic analysis calculated the initial muzzle velocity as well as the impact on the retinal surface at approximately 15 mm of the injected drug delivery system implant in both groups. A series of drug delivery system implant positions was obtained and graphically plotted over time.
RESULTS: High-speed real-time recordings revealed that the entire movement of the DEX implant lasted between 28 milliseconds and 55 milliseconds in Group A and 1 millisecond and 7 milliseconds in Group B. The implants moved with a mean muzzle velocity of 820 ± 350 mm/s (±SD, range, 326-1,349 mm/s) in Group A and 817 ± 307 mm/s (±SD, range, 373-1,185 mm/s) in Group B. In both groups, the implant gradually decelerated because of drag force. With greater distances, the velocity of the DEX implant decreased exponentially to a complete stop at 13.9 mm to 24.7 mm in Group A and at 6.4 mm to 8.0 mm in Group B. Five DEX implants in Group A reached a total distance of more than 15 mm, and their calculated mean velocity at a retinal impact of 15 mm was 408 ± 145 mm/s (±SD, range, 322-667 mm/s), and the consecutive normalized energy was 0.55 ± 0.44 J/m (±SD). In Group B, none of the DEX implants reached a total distance of 6 mm or more. An accidental application at an angle of 30 grade and consecutively reduced distance of approximately 6 mm may result in a mean velocity of 844 and mean normalized energy of 0.15 J/m (SD ± 0.47) in a water-filled eye.
CONCLUSION: The muzzle velocity of DEX implants is approximately 0.8 m/s and decreases exponentially over distance. The drag over time in vitreous is faster than in water. The calculated retinal impact energy does not reach reported damage levels for direct foreign bodies or other projectiles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23060033     DOI: 10.1097/IAE.0b013e31825699e5

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  17 in total

1.  Anterior vitreous displacement of the intravitreal dexamethasone implant (Ozurdex).

Authors:  S Wai Ch'ng; S Padroni; S Banerjee
Journal:  Eye (Lond)       Date:  2013-12-13       Impact factor: 3.775

2.  Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO study.

Authors:  Carsten H Meyer; Zengping Liu; Christian K Brinkmann; Eduardo B Rodrigues; Thomas Bertelmann
Journal:  J Ocul Pharmacol Ther       Date:  2014-05-06       Impact factor: 2.671

3.  [Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy].

Authors:  L-O Hattenbach; C Kuhli-Hattenbach; C Springer; J Callizo; H Hoerauf
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

4.  [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].

Authors:  K Schmitz; M Maier; C R Clemens; F Höhn; J Wachtlin; F Lehmann; T Bertelmann; K Rüdiger; M Horn; A Bezatis; G Spital; C H Meyer
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

5.  Management of foveal adhesion of a dexamethasone implant.

Authors:  Yuji Itoh; Sunil K Srivastava; Justis P Ehlers
Journal:  Acta Ophthalmol       Date:  2015-10-07       Impact factor: 3.761

6.  Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.

Authors:  Ryan A Kelley; Alireza Ghaffari; Yan Wang; Stephanie Choi; Jonathan R Taylor; Rachel R Hartman; Uday B Kompella
Journal:  J Ocul Pharmacol Ther       Date:  2020-04-24       Impact factor: 2.671

7.  Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema.

Authors:  Elena Pacella; Anna Rita Vestri; Roberto Muscella; Maria Rosaria Carbotti; Massimo Castellucci; Luigi Coi; Paolo Turchetti; Fernanda Pacella
Journal:  Clin Ophthalmol       Date:  2013-07-16

8.  Vitrectomy in full thickness macular holes on top of a pigment epithelial detachment in age-related macular degeneration (AMD). Surgical consideration and review of the literature.

Authors:  Paula S Meyer; Marc T Kammann; Carsten H Meyer
Journal:  Am J Ophthalmol Case Rep       Date:  2021-07-10

Review 9.  Dexamethasone intravitreal implant in the treatment of diabetic macular edema.

Authors:  Pravin U Dugel; Francesco Bandello; Anat Loewenstein
Journal:  Clin Ophthalmol       Date:  2015-07-16

10.  Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.

Authors:  Fernanda Pacella; Adriana Francesca Ferraresi; Paolo Turchetti; Tommaso Lenzi; Rosalia Giustolisi; Andrea Bottone; Valeria Fameli; Maria Rosaria Romano; Elena Pacella
Journal:  Ophthalmol Eye Dis       Date:  2016-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.